United States: "Nearly All" Not Quite Good Enough To Achieve Discretionary Denial Under §325(d) - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

In Fusion Pharms., Inc. v. Univerität Heidelberg, IPR2023-00551, the Patent Trial and Appeal Board ("PTAB") instituted inter partes review ("IPR"), rejecting Patent Owner's §325(d) argument.